|
|
|
|
| LEADER |
05623cam a2200745 i 4500 |
| 001 |
1286665319 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
211130s2022 sz a o 000 0 eng d |
| 019 |
|
|
|a 1286709861
|a 1286791224
|a 1287138549
|a 1294366471
|a 1296666997
|
| 020 |
|
|
|a 9783030812614
|q (electronic bk.)
|
| 020 |
|
|
|a 3030812618
|q (electronic bk.)
|
| 020 |
|
|
|z 9783030812607
|
| 020 |
|
|
|z 303081260X
|
| 024 |
7 |
|
|a 10.1007/978-3-030-81261-4
|2 doi
|
| 035 |
|
|
|a (OCoLC)1286665319
|z (OCoLC)1286709861
|z (OCoLC)1286791224
|z (OCoLC)1287138549
|z (OCoLC)1294366471
|z (OCoLC)1296666997
|
| 037 |
|
|
|b Springer
|
| 040 |
|
|
|a YDX
|b eng
|e rda
|e pn
|c YDX
|d GW5XE
|d EBLCP
|d OCLCF
|d OCLCO
|d DCT
|d DKU
|d N$T
|d AUD
|d OCLCO
|d OCLCQ
|d CASUM
|d OCLCO
|d OCLCL
|
| 049 |
|
|
|a COM6
|
| 050 |
|
4 |
|a R895
|b .N83 2022
|
| 072 |
|
7 |
|a MMN
|2 bicssc
|
| 072 |
|
7 |
|a MED080000
|2 bisacsh
|
| 072 |
|
7 |
|a MKR
|2 thema
|
| 082 |
0 |
4 |
|a 616.07/575
|2 23
|
| 245 |
0 |
0 |
|a Nuclear medicine and immunology /
|c Sara Harsini, Abass Alavi, Nima Rezaei, editors.
|
| 264 |
|
1 |
|a Cham :
|b Springer,
|c [2022]
|
| 264 |
|
4 |
|c ©2022.
|
| 300 |
|
|
|a 1 online resource :
|b illustrations (chiefly color)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent.
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia.
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier.
|
| 347 |
|
|
|a text file.
|
| 347 |
|
|
|b PDF.
|
| 520 |
|
|
|a This book explores the close connection between immunology and nuclear medicine, which has led to radioimmunoimaging and radioimmunotherapy (RIT). Molecular imaging with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is increasingly being used to diagnose, characterize, and monitor disease activity in the context of inflammatory disorders of known and unknown etiology, such as sarcoidosis, atherosclerosis, vasculitis, inflammatory bowel disease, rheumatoid arthritis, and degenerative joint disease. The first chapters discuss the various radiopharmaceutical agents and radiolabeled preparations that have been employed in inflammation imaging. Of these, FDG-PET imaging has been shown to have the great value in the detection of inflammation and has become the centerpiece of several initiatives over the last several years. This very powerful technique will play an increasingly important role in the management of patients with inflammatory conditions in the future. The book also explores the growing role of nuclear medicine and molecular imaging in the diagnosis and treatment of cancer. The rapid pace of change has been fueled by advances in our understanding of tumor biology, on the one hand, and the development of specifically targeted medical therapies, diagnostic agents, and radiotherapies, on the other. Written by leading international experts in the field, this book is an invaluable tool for nuclear medicine physicians, radiologists, oncologists, and immunologists.
|
| 505 |
0 |
|
|a 1. Molecular Imaging in Inflammatory and Autoimmune Disorders -- 2. Gallium Imaging of Infection and Inflammation -- 3. 111Indium-Labeled Leukocyte Imaging of Infection and Inflammation -- 4. 99mTc-HMPAO-Labeled-Leukocyte Imaging of Infection and Inflammation -- 5. FDG-PET Imaging of Infection and Inflammation -- 6. Imaging Procedures with Radiolabeled Monoclonal Antibodies -- 7. Dosimetric Principles of Targeted Radiotherapy -- 8. Radioimmunotherapy (RIT) -- 9. Peptide Receptor Radionuclide Therapy (PRRT) -- 10. Tumor Architecture and Targeted Delivery -- 11. Antibodies and Novel Constructs for Tumor Targeting -- 12. Pretargeted Radioimmunotherapy of Cancer -- 13. Radioimmunotherapy of Lymphoma -- 14. Radioimmunotherapy in Brain Tumors -- 15. Radioimmunotherapy of Pancreatic Adenocarcinoma -- 16. Radioimmunotherapy of Renal Cell Carcinoma -- 17. Radioimmunotherapy of Prostate Carcinoma -- 18. Radioimmunotherapy of Ovarian Cancer -- 19. Targeted Radiotherapy in the Treatment of Osteosarcoma -- 20. Targeted Radiotherapy of Neuroblastoma -- 21. Targeted Radiotherapy of Squamous Cell Carcinoma of the Head and Neck -- 22. Moving Forward: Expected Opportunities for the Development of New Therapeutic Agents -- 23. Translation of Radiopharmaceuticals from Bench to Bedside.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed December 8, 2021).
|
| 650 |
|
0 |
|a Nuclear medicine.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
2 |
|a Nuclear Medicine.
|
| 650 |
|
2 |
|a Allergy and Immunology.
|
| 650 |
|
6 |
|a Médecine nucléaire.
|
| 650 |
|
6 |
|a Immunologie.
|
| 650 |
|
7 |
|a Immunology.
|2 fast.
|
| 650 |
|
7 |
|a Nuclear medicine.
|2 fast.
|
| 655 |
|
0 |
|a Electronic books.
|
| 655 |
|
4 |
|a Index not Present.
|
| 700 |
1 |
|
|a Harsini, Sara,
|e editor.
|
| 700 |
1 |
|
|a Alavi, Abass,
|e editor.
|
| 700 |
1 |
|
|a Rezaei, Nima,
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 776 |
0 |
8 |
|i Print version:
|z 303081260X
|z 9783030812607
|w (OCoLC)1257402676.
|
| 907 |
|
|
|a .b66230846
|b multi
|c -
|d 230413
|e 240516
|
| 998 |
|
|
|a (2)cue
|a cu
|b 240404
|c m
|d z
|e -
|f eng
|g sz
|h 0
|i 2
|
| 948 |
|
|
|a MARCIVE Overnight, in 2024.04
|
| 948 |
|
|
|a MARCIVE Comprehensive, in 2023.05
|
| 994 |
|
|
|a 92
|b COM
|
| 995 |
|
|
|a Loaded with m2btab.ltiac in 2024.04
|
| 995 |
|
|
|a Loaded with m2btab.elec in 2024.04
|
| 995 |
|
|
|a Loaded with m2btab.ltiac in 2023.05
|
| 995 |
|
|
|a Loaded with m2btab.elec in 2023.04
|
| 999 |
|
|
|e z
|
| 999 |
|
|
|a cue
|
| 989 |
|
|
|d cueme
|e - -
|f - -
|g -
|h 0
|i 0
|j 200
|k 240404
|l $0.00
|m
|n - -
|o -
|p 0
|q 0
|t 0
|x 0
|w SpringerLink
|1 .i15158722x
|u http://ezproxy.coloradomesa.edu/login?url=https://link.springer.com/10.1007/978-3-030-81261-4
|3 SpringerLink
|z Click here for access
|